Showing results (1-10 of 80) with videos related to
Sort By:
Pageof 8
Cancer|June 21, 2014
The MAPK pathway across different malignancies: a new perspectiveMauricio Burotto, Victoria L Chiou, Jung-Min Lee, et al.Expert Opinion on Biological Therapy|July 11, 2017
MABp1 for the treatment of colorectal cancerGeraldine O'Sullivan Coyne, Mauricio BurottoExpert Opinion on Biological Therapy|July 15, 2014
Clinical experience with ramucirumab : outcomes in breast cancerGeraldine O'Sullivan Coyne, Mauricio BurottoExpert Review of Hematology|May 12, 2016
Double hit lymphoma: from biology to therapeutic implicationsMauricio Burotto, Alejandro Berkovits, Kieron DunleavyJournal of Global Oncology|July 27, 2019
Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy?Alex Renner, Mauricio Burotto, Carlos RojasRevista Medica De Chile|November 17, 2004
[Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83]Mauricio Burotto, Luigi Gabrielli, Nicolás CrossleyExpert Review of Molecular Diagnostics|February 13, 2018
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road aheadPradnya D Patil, Mauricio Burotto, Vamsidhar VelchetiThe Oncologist|June 26, 2024
Predictors of response to immunotherapy in colorectal cancerJaime González-Montero, Carlos I Rojas, Mauricio BurottoTherapeutic Delivery|April 7, 2026
Subcutaneous atezolizumab for the treatment of non-small cell lung cancerJaime González-Montero, Carlos I Rojas, Mauricio BurottoPageof 8